A hospital buys an AI tool that reads CT scans. Six months later the vendor ships a better model — same algorithm, sharper accuracy. Under the old rulebook, that upgrade can mean a fresh, slow re-review. On July 3, 2025, China's drug regulator said that should not always be the case, at least not for artificial-intelligence medical devices.
Key takeaways
- China's National Medical Products Administration (国家药品监督管理局, NMPA) published "Announcement No. 63 of 2025" on July 3, 2025, setting out ten support measures for high-end medical devices.
- For AI medical devices, the agency will simplify change registration when the core algorithm is unchanged but its performance is optimized — a common real-world upgrade pattern.
- It will develop technical guidance or review points for multi-disease and large-model (大模型) AI medical devices, and explore using standardized test databases for performance evaluation.
- The same AI software function registered on different hardware platforms could face lighter review if the manufacturer proves the platforms are equivalent.
- Several AI items are commitments to study and draft (研究制定 / 探索完善), not finalized rules — the announcement itself took effect on publication, but the detailed guidance is still to come.
What changed, and what didn't
NMPA's announcement targets four device families: medical robots (医用机器人), high-end medical imaging equipment, AI medical devices, and new biomaterials. The ten measures run from special-approval fast-tracks to classification rules, standards, post-market monitoring, and communication mechanisms.
For AI specifically, the most concrete relief is on change registration. Today, improving a model's performance often triggers a new registration cycle even when nothing about the underlying algorithm changed. The July announcement says the agency will simplify the change-registration requirements for exactly that case — core algorithm unchanged, performance optimized. That matters because AI models in clinics are refreshed far more often than traditional hardware, and every unnecessary cycle is time a useful tool spends stuck in paperwork.
The announcement also pushes the standards machine. NMPA says it will accelerate the revision of basic, general, and method standards for medical robots, AI medical devices, and high-end imaging, and plans to set up dedicated standardization technical bodies for AI medical devices and medical robots. Standards are the scaffolding that lets a "simplified" review actually be reproducible across reviewers.
The large-model question
The announcement also says NMPA will research and develop (研究制定) technical guidance or review points for multi-disease and large-model AI medical devices. That wording matters: it is a pledge to write the rules, not the rules themselves. As of publication, China did not have a finished, published review standard aimed specifically at large foundation models used in medical devices, so vendors building those products are still operating in a gray zone the agency has now said it will fill.
Alongside that, the agency will explore (探索完善) using curated test or evaluation databases (测评数据库) to assess AI device performance, and it will study how to classify and name new modalities like medical large models and imaging-preprocessing software. Again, "explore" signals work to come rather than a live requirement.
Cross-platform and brain-computer interface
One quiet but useful change: where the same AI software function is registered on different platforms, the agency will simplify the review if the manufacturer can prove the platforms are equivalent. For vendors who certify a product on one hospital's server stack and want to port it elsewhere, that could remove duplicate paperwork.
The announcement also nods to brain-computer interfaces (脑机接口): NMPA says it will coordinate with relevant departments to issue support policies for BCI-based medical devices. That is a forward-looking commitment, not a published policy, and it sits alongside a separately published industry standard on BCI medical-device terminology that appeared later in 2025.
Why it matters
China has approved a long line of innovative medical devices — in an August 2025 reply to a legislative proposal, NMPA said 361 innovative devices and 153 clinically urgent priority devices had been approved to date. AI and medical robots are among the fastest-moving categories, and the bottleneck has increasingly been regulatory clarity rather than the technology.
The announcement does not lower safety bars; it tries to make the path predictable. Simplified change registration, defined test databases, and clearer classification all reduce the guesswork for manufacturers deciding whether to invest in a China-specific clinical and regulatory track.
Honest limitations
This article describes NMPA Announcement No. 63 of 2025 as published on the agency's official notice page on July 3, 2025; it does not reproduce the full ten measures or cover other NMPA device rules. Several AI-related items are framed by the agency as "research and develop" or "explore," meaning the concrete technical guidance and test-database requirements are not yet finalized and may differ from what the announcement previews. The 361 / 153 approval figures come from a separate August 2025 NMPA reply, not the announcement, and reflect cumulative counts up to that reply. We did not assess how individual provincial review bodies will implement the measures, and timelines for the promised guidance are not stated in the sources reviewed.
What readers can do now
- If you build or buy AI medical devices in China, map your product's upgrade cadence to the new change-registration relief — algorithm-only performance bumps should now face a lighter path.
- Track NMPA's technical-guidance page for the forthcoming multi-disease and large-model review points and any test-database standards before committing to a China clinical plan.
- If you work in brain-computer interface medical products, watch for the cross-department support policy the announcement previews rather than assuming it is already in force.
